| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Development Officer
1 company
Matis Louis is a SVP, Chief Development Officer at PALVELLA THERAPEUTICS, INC.. Recent SEC Form 4 filings include 2 buys and 0 sells.
Estimated insider holdings value: $1.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2016 | PVLA Palvella Therapeutics, Inc. | SVP, Chief Development Officer | Buy | 10,000 | $1.70 | $17,037.45 | +479.6% |